Role of IV Calcium to Prevent Diltiazem-related Hypotension

PHASE4CompletedINTERVENTIONAL
Enrollment

217

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

June 1, 2024

Study Completion Date

July 1, 2024

Conditions
Atrial FibrillationRapid Ventricular ResponseHypotension Drug-Induced
Interventions
DRUG

Sodium chloride

The Diltiazem monotherapy group received 6.66 mL of IV sodium chloride 0.9% (NaCl) prior to receiving IV weight-adjusted diltiazem.

DRUG

90 mg of calcium

The Diltiazem with 90 mg calcium group received 3.33 mL of IV calcium chloride (CaCl2, 90 mg) and 3.33 mL of IV NaCl 0.9% as pretreatment over 5-10 min prior to receiving IV diltiazem.

DRUG

180 mg Calcium

The Diltiazem with 180 mg calcium group received 6.66 mL of IV CaCl2 (180 mg) as pretreatment prior to receiving IV diltiazem.

Trial Locations (1)

34265

Haseki Training and Research Hospital, Istanbul

All Listed Sponsors
lead

Haseki Training and Research Hospital

OTHER